FCGR3B

Across TCGA pan-cancer cohorts, FCGR3B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FCGR3B data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher FCGR3B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FCGR3B expression acts as an unfavorable survival marker.

OV, COAD, and UCEC are the cancer types where FCGR3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.160	0.541	.003	18	view →
COAD	OS	Median	II,III,IV	0.168	0.788	.005	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.326	0.642	.040	6	view →
LIHC	OS	Median	All	0.258	0.773	.018	3	view →
LUSC	OS	Median	All	0.414	0.823	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FCGR3B–OV (DFS)

Open the OV breakdown →